During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
The deepest mechanistic evidence, going back to Pickart's earliest work, where GHK-Cu improved the speed and quality of tissue repair.[1] This is the area with the strongest biological rationale, even if it's largely from cell and animal models rather than large human trials
The Gray Zone: Synthetic Nootropics There is a hazy gray area beyond pharmaceutical drug and dietary supplement nootropics: synthetics
The clinicopathological characteristics of patient samples are provided in Supplementary Table S1 for BS-PCR sequencing study and in Supplementary Table S2 for qMSP PCR assay
Homocysteine accumulates in the blood, causing vascular damage and micro-clotting, while downstream glutathione synthesis grinds to a halt
